Company profile: Trail Bio
1.1 - Company Overview
Company description
- Provider of human iPSC-derived cells and optimization technologies for drug discovery and cell therapies. Offers the HD-DoE Technology Platform, applying high-dimensional design-of-experiments to optimize cell growth and differentiation, and TrailBio Cells. Portfolio includes TrailBio Pre-Myelinating Oligodendrocytes Kit, Vascular Leptomeningeal Cells, and Insulin-Producing Islet-Like Clusters for screening and disease modeling.
Products and services
- TrailBio Cells: Research-grade iPSC-derived human cells used for research in drug discovery and cell therapies, offered for various applications
- HD-DoE™ Technology Platform: High-dimensional design-of-experiments system that optimizes iPSC growth and differentiation into specialized human cells, addressing cell purity and potency challenges to enable precise cellular therapies
- TrailBio Insulin-Producing Islet-Like Clusters: In vitro iPSC-derived immature islet-like cell assemblies used for screening compounds affecting pancreatic function, supporting diabetes drug development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Trail Bio
CellTran
HQ: United Kingdom
Website
- Description: Provider of biotechnology-based cell therapy and wound management products, focused on research and development for tissue regeneration and wound healing. Offers Myskin for difficult-to-heal wounds, Lyphoderm, a hydrophilic gel from freeze-dried lysate of cultured human keratinocytes, and Ulcodress.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CellTran company profile →
Advanced Cell Technology
HQ: United States
Website
- Description: Provider of stem cell-based regenerative therapies, including human embryonic stem cell-derived retinal pigment epithelial (RPE) therapy for retinal degenerative diseases such as Stargardt's disease and dry age-related macular degeneration; a hemangioblast (HG) platform for blood and cardiovascular diseases with CHA Biotech; and myoblast autologous adult stem cell therapy for heart failure, advanced cardiac disease, myocardial infarction, and ischemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advanced Cell Technology company profile →
Regenicin
HQ: United States
Website
- Description: Provider of regenerative cell therapy development, operating as a biotechnology company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Regenicin company profile →
Medistem
HQ: United States
Website
- Description: Provider of adult stem cell-based therapeutic products through development, acquisition, and commercialization. Founded in 2005, the company holds 16 families of patent applications, has numerous scientific publications, and generates revenue by out-licensing certain technologies. Main candidate: Endometrial Regenerative Cell (ERC).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medistem company profile →
Histogenics
HQ: United States
Website
- Description: Provider of tissue regeneration treatments for long-lasting joint repair.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Histogenics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Trail Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Trail Bio
2.2 - Growth funds investing in similar companies to Trail Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Trail Bio
4.2 - Public trading comparable groups for Trail Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →